Kailos Genetics Announces Co-marketing Agreement with Illumina, Inc. for Pharmacogenetics Solution for Research

Agreement expands Kailos’ use of market-leading next-generation sequencing solutions March 21, 2017 06:00 AM Pacific Daylight Time HUNTSVILLE, Ala.–(BUSINESS WIRE)–Kailos Genetics, a personalized medicine company offering a leading-edge suite of tools for next-generation sequencing (NGS)-based assays, today announced it has entered into a co-marketing agreement with Illumina, Inc. (NASDAQ: ILMN). Under the terms of the... Read more

Agilent Technologies Enhances Exome Sequencing for Clinical Research

New Target Enrichment Product Delivers Deep Coverage of Disease Relevant Content SANTA CLARA, Calif., March 21, 2017 Agilent Technologies Inc. (NYSE: A) today introduced a new target enrichment solution for next-generation DNA sequencing. Agilent SureSelect Clinical Research Exome V2 delivers more than 1,000 additional, disease relevant targets compared to the company’s earlier version of the... Read more

Thermo Fisher Scientific and the Cell and Gene Therapy Catapult Collaborate to Optimise Advanced Therapy Supply Chain

LONDON–(BUSINESS WIRE)–To help address the challenges surrounding supply chain management for cell and gene therapy around the globe, Thermo Fisher Scientific, the world leader in serving science, today announced a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult) to provide developers with both the manufacturing capability and distribution, logistics, and storage capacity needed... Read more

New Comprehensive Carrier Screening Research Assay Features Richest Pan-Ethnic Panel for Detection of Multiple Genetic Variations in Inherited Disease

CARLSBAD, Calif. & PHOENIX–(BUSINESS WIRE)–A new high-throughput, microarray-based assay designed to detect more than 6,000 genomic variations associated with inherited disease now provides molecular genetics laboratories with a consolidated and automated, single pan-ethnic solution for expanded carrier status research. Thermo Fisher Scientific announced the CarrierScan™ Assay today at the 2017 ACMG Annual Clinical Genetics Meeting... Read more

Phenomenex Expands Kinetex F5 (Pentafluorophenyl) HPLC and UHPLC Core-Shell Line to 5 µm for Preparative LC

Torrance, CA (March 21, 2017) – Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, introduces a new 5 µm particle size to its family of Kinetex F5 pentafluorophenyl propyl (PFP) core-shell columns, extending the versatility of F5 to preparative LC and purification work. Kinetex F5 is... Read more

Agilent Technologies Hires Samraat “Sam” Raha to Head Strategy and Corporate Development

Former Agilent Commercial VP Brings Deep Industry and Marketing Experience to New Role SANTA CLARA, Calif., March 20, 2017 Agilent Technologies Inc. (NYSE: A) today announced that Samraat “Sam” Raha has been named senior vice president of strategy and corporate development, reporting to Agilent President and CEO Mike McMullen. Raha will serve as strategic lead... Read more

Thermo Fisher Scientific Introduces the QuantStudio 5 Real-Time PCR System for the Modern Forensic Laboratory

CARLSBAD, Calif.–(BUSINESS WIRE)–Forensic scientists who want to modernize their laboratories now have access to the Applied Biosystems QuantStudio 5 Real-Time PCR System for Human Identification. Paired with the complementary analysis software and Thermo Fisher Scientific’s leading DNA chemistries, the complete solution is designed to meet evolving needs and help labs stay ahead of future technological... Read more

New Family of Zebron GC Columns for Fast Highly Selective FAME Analysis

Torrance, Calif. (March 14, 2017) – Phenomenex Inc., a global leader in the research, design and manufacture of advanced technologies for the separation sciences, introduces a trio of Zebron™ GC columns specially developed for the analysis of fatty acid methyl esters (FAME) in food. Identification and measurement of these compounds in food products such as... Read more

RedShift BioAnalytics, Inc. Completes $11.0 million Series C Financing

Financing to Drive Commercialization of Next Generation Biotechnology Instrumentation for Drug Discovery and Development BURLINGTON, MA – March 13, 2017 – RedShift BioAnalytics, Inc., an innovative provider of bioanalytical instrumentation for the research, development and manufacturing of protein therapeutic drugs, today announced the closing of the Company’s $11.0 million Series C Preferred Stock financing. The... Read more